A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > BUSINESS
BUSINESS
- NBI, Eli Lilly Japan to Establish “Special Position” for Trazenta in DPP-4 Inhibitor Market
October 18, 2011
- US MediciNova to Jointly Conduct Clinical Trials of MN-221 with Kissei
October 17, 2011
- Bayer, Onyx Restructure Global Oncology Partnership
October 17, 2011
- Ube, Santen Enter into License Agreement for EP2 Agonist
October 17, 2011
- MTPC Licenses Novel Pruritus Treatment from Toray in North America
October 17, 2011
- Otsuka Medical Devices to Acquire KiSCO Group Companies
October 17, 2011
- IBL Launches ANGPTL2 Assay Kit
October 17, 2011
- 60% Rule Likely to Replace 70% Rule for New Generics: Mr Kikuchi of Nichi-Iko MPI
October 17, 2011
- CMIC Forms a Chinese Joint Venture, Making Capital Investment in Local CRO
October 14, 2011
- Nichi-Iko to Be Delisted from OSE, NSE
October 14, 2011
- Nichi-Iko Revises Full-year Forecasts Downward Despite Double-digit Growth in Sales
October 14, 2011
- Daiichi Sankyo Resubmits NDA for Iron Deficiency Anemia Treatment Injectafer to FDA
October 14, 2011
- Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
- Nihon Chouzai Aims to Triple Home Healthcare, Nursing Facility Business in 2 Years
October 14, 2011
- Eli Lilly Japan Applies for Strattera for AD/HD in Adults
October 13, 2011
- Hisamitsu Posts 2.7% Loss in Mar-Aug Results on Shipping Adjustments of Main Products
October 13, 2011
- Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
- Hisamitsu: Sales of Norspan Lower Than Expected
October 13, 2011
- CHMP Recommends Approval of Novo’s Levemir for Type I Diabetes in Children
October 13, 2011
- Asahi Kasei Pharma to Start Clinical Trials in 2012 of US Transdermal Patch Formulation
October 12, 2011
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…